These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12769627)

  • 1. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.
    Millan MJ
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):191-213. PubMed ID: 12769627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
    Millan MJ
    Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics.
    Bennett S; Gronier B
    Eur J Pharmacol; 2005 Dec; 527(1-3):52-9. PubMed ID: 16307739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine modulators in schizophrenia.
    Javitt DC
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
    Cascella NG; Macciardi F; Cavallini C; Smeraldi E
    J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.
    Chaves C; Marque CR; Trzesniak C; Machado de Sousa JP; Zuardi AW; Crippa JA; Dursun SM; Hallak JE
    Braz J Med Biol Res; 2009 Nov; 42(11):1002-14. PubMed ID: 19855900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex.
    Fujihira T; Kanematsu S; Umino A; Yamamoto N; Nishikawa T
    Neurochem Int; 2007; 51(2-4):233-6. PubMed ID: 17662507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-alanine added to antipsychotics for the treatment of schizophrenia.
    Tsai GE; Yang P; Chang YC; Chong MY
    Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
    Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade.
    Heresco-Levy U
    Int J Neuropsychopharmacol; 2000 Sep; 3(3):243-258. PubMed ID: 11343602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat.
    Gozzi A; Herdon H; Schwarz A; Bertani S; Crestan V; Turrini G; Bifone A
    Psychopharmacology (Berl); 2008 Dec; 201(2):273-84. PubMed ID: 18704372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
    Fone KCF; Watson DJG; Billiras RI; Sicard DI; Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Mol Neurobiol; 2020 May; 57(5):2144-2166. PubMed ID: 31960362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat.
    Chiusaroli R; Garofalo P; Espinoza S; Neri E; Caselli G; Lanza M
    Pharmacol Res; 2010 May; 61(5):430-6. PubMed ID: 20045056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.